 In previously-untreated subjects with CLL, fludarabine and rituximab with or without cyclophosphamide FR or FCR produces complete responses CR of 40-80. The major complication of FCR has been grade 34 neutropenia which was reduced using a lower dose of fludarabine and cyclophosphamide FCR-Lite The objective of this study is to evaluate the minimal residual disease MRD complete response rate using the 2008 IWCLL guidelines after 4 cycles of FCR-Lite plus lenalidomide in subjects with previously untreated CLL. Lenalidomide is active in frontline treatment of CLL as well as in patients with refractory disease. MRD has been demonstrated to be a sensitive surrogate marker for progression-free survival. If patients are MRD negative complete responders CR they will stop at 4 cycles of FCR-Lite followed by the lenalidomide consolidationmaintenance arm of the study. If they have a MRD positive CR or partial response PR they will continue with 2 additional cycles of FCR-Lite plus lenalidomide followed by lenalidomide consolidationmaintenance. They will be re-tested for MRD after the 6th cycle of FCR-Lite and after 6 and 12 months of lenalidomide monotherapy If they have no response NR or progressive disease PD following 4 cycles of FCR-Lite plus lenalidomide they will be removed from the study. 